Pipeline

Our programs span multiple CNS pathophysiologies, each addressing significant unmet medical needs in rare disease populations. If you would like to explore partnership or discuss synergies with your existing portfolio, please contact us at info@kalevalatherapeutics.com

PRECLINICAL

PHASE 1

PHASE 2/3

COMMERCIAL

KV-3004M

Gaucher Disease

FDA ODD GRANTED

KV-1004R

Sturge-Weber Syndrome

KV-3002R
KV-1001R

Histiocytic Disorders

KV-3001R

Undisclosed Indication

Phase 1 safety established through prior clinical use for repurposed drugs in these specific indications.

Therapeutic Focus Areas

Cerebrovascular & Neurovascular Disorders: Vascular malformations and thrombotic vasculopathies affecting CNS function, including conditions with seizure and stroke manifestations
CNS manifestations of histiocytosis: Histiocytic disorders with central nervous system involvement, focusing on inflammatory and infiltrative pathologies
Lysosomal Storage & Neurodegeneration: Lysosomal storage diseases and proteinopathies with progressive neurological decline
Channelopathies & Neuromuscular Disorders: Ion channel disorders and neuromuscular transmission defects affecting motor function and paroxysmal neurological symptoms